{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:15:44Z","timestamp":1793218544638,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103198","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T06:41:10Z","timestamp":1607841670000},"page":"103198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings"],"prefix":"10.1016","volume":"157","author":[{"given":"Matteo","family":"Ferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Dolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"La Civita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zappavigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"de Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Arianna","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Scafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Klain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.103198_bib0005","article-title":"Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102992","article-title":"Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis","author":"Buonerba","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.03.014","article-title":"Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)","author":"D\u2019Angelillo","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103198_bib0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate Cancer Previously treated with abiraterone acetate plus prednisone for \u226524 weeks in Europe","volume":"74","author":"de Bono","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2018.12.010","article-title":"Oligometastatic prostate Cancer: is it only a matter of perspective?","author":"Di Lorenzo","year":"2019","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103198_bib0045","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/10898600-000000000-00000","article-title":"Castration-resistant prostate cancer: current and emerging treatment strategies","volume":"70","author":"Di Lorenzo","year":"2010","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103198_bib0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-020-00888-5","article-title":"Systemic treatment for metastatic hormone sensitive prostate Cancer: a comprehensive meta-analysis evaluating efficacy and safety in specific sub-groups of patients","volume":"40","author":"Di Nunno","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0055","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2020-0557","article-title":"Apalutamide for the treatment of metastatic castration-sensitive prostate cancer","author":"Dror","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0060","article-title":"Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing","author":"Fan","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0065","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103198_bib0075","first-page":"508","article-title":"Management of patients with advanced prostate Cancer: report of the advanced prostate Cancer consensus conference","volume":"77","author":"Gillessen","year":"2019","journal-title":"Eur. Urol. 2020"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103198_bib0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate Cancer: report of the advanced prostate Cancer consensus conference 2019[Formula presented]","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial","author":"Gravis","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2020.103198_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201cLow-risk\u201d Metastatic Hormone-sensitive Prostate Cancer(figure presented.)","author":"Hoyle","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.05.005","article-title":"Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: how prognostic classification impact treatment decisions","author":"Iacovelli","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103198_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2020.103198_bib0110","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/j.annonc.2020.08.871","article-title":"611O Abiraterone acetate plus prednisolone for hormone-na\u00efve prostate cancer (PCa): long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)","volume":"31","author":"James","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103198_bib0120","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JU.0000000000000636","article-title":"New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate Cancer: results from a network meta-analysis","volume":"203","author":"Marchioni","year":"2020","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103198_bib0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P R. Epidemiology of Prostate Cancer","year":"2019","journal-title":"World J. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2020.103198_bib0130","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2174\/138945012803529956","article-title":"New perspectives in the therapy of castration resistant prostate Cancer","volume":"13","author":"Rescigno","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.critrevonc.2020.103198_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate Cancer: a systematic review and network meta-analysis","author":"Sathianathen","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2020.103198_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.06.033","article-title":"Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer","author":"Swami","year":"2020","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103198_bib0145","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820303346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820303346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:48:22Z","timestamp":1760903302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820303346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S1040842820303346"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103198","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103198"}}